OMGA Live signaler | Maksimer profitt med Getagraph.com

SELG 115743 min ago

@ $3.97

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -35.01%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 1.28 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	387 361
Gjennomsnittsvolum	399 225
Markedsverdi	142.30M
EPS	$-0.370 ( 2024-05-02 )
Neste inntjeningsdato	( $-0.330 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.00900 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Mccauley Thomas	Buy	125 000	Stock Option (Right to Buy)
2024-02-07	Mccauley Thomas	Buy	75 000	Stock Option (Right to Buy)
2024-02-07	Karande Mahesh	Buy	314 326	Stock Option (Right to Buy)
2024-02-07	Karande Mahesh	Buy	209 551	Stock Option (Right to Buy)
2024-02-07	Moore Yan	Buy	110 000	Stock Option (Right to Buy)

INSIDER POWER
98.71
Last 90 transactions
Buy: 34 429 434 \| Sell: 15 655 033

Volum Korrelasjon

Lang: -0.36 (neutral)

Kort: 0.00 (neutral)

Signal:(42.674) Neutral

Omega Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
BOTJ	0.832
OPRX	0.817
SYRS	0.811
XENE	0.804
CPIX	0.801
FRST	0.801

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Omega Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.46
( neutral )

0.54
( weak )

0.00
( neutral )

-0.60
( weak negative )

0.09
( neutral )

Omega Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$3.09M
Bruttogevinst:	$-3.68M (-118.84 %)
EPS:	$-1.800

FY	2023
Omsetning:	$3.09M
Bruttogevinst:	$-3.68M (-118.84 %)
EPS:	$-1.800

FY	2022
Omsetning:	$2.07M
Bruttogevinst:	$-3.12M (-150.36 %)
EPS:	$-2.14

FY	2021
Omsetning:	$144 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.11

Financial Reports:

No articles found.

Omega Therapeutics, Inc.

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.